---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-039770"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:27:06.053080+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed

## Summary
- Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.
- CEO Paula Ragan, Ph.D., and CFO Adam S. Mostafa resigned effective Aug 12, 2025; no disagreement cited.
- Adam Raymond Craig, M.D., Ph.D., appointed Executive Chairman and principal executive officer; John Volpone named President.
- David H. Kirske appointed CFO, Secretary, principal financial and accounting officer.
- Proceeds to fund continued development of mavorixafor for chronic neutropenia and commercialization for WHIM.

## SEC filing metadata
- accession: 0001628280-25-039770
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/0001628280-25-039770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/xfor-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-039770
- JSON: https://secwatch.observer/filing/0001628280-25-039770.json
- Plain text: https://secwatch.observer/filing/0001628280-25-039770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.